These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 9491958)

  • 1. Multivessel coronary thrombosis treated with abciximab (ReoPro) in a patient with essential thrombocythemia.
    Michaels AD; Whisenant B; MacGregor JS
    Clin Cardiol; 1998 Feb; 21(2):134-8. PubMed ID: 9491958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Exercise-induced left arm pain and thrombocytosis].
    Kunz I; Spada S; Sütsch G; Ruggieri F
    Praxis (Bern 1994); 2005 Apr; 94(15):599-603. PubMed ID: 15884726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Acute thrombo-embolic elevated ST infarct in a patient with essential thrombocytosis].
    Doesch C; May AE; Toncar-Pflumm G; Anders N; Geisler T; Kröber S; Kandolf R; Gawaz M
    Internist (Berl); 2007 Nov; 48(11):1282, 1284-6, 1288-9. PubMed ID: 18026768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
    EPISTENT Investigators
    Lancet; 1998 Jul; 352(9122):87-92. PubMed ID: 9672272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trial. EPIC Investigators. Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic Complications.
    Khan MM; Ellis SG; Aguirre FV; Weisman HF; Wildermann NM; Califf RM; Topol EJ; Kleiman NS
    J Am Coll Cardiol; 1998 Jan; 31(1):31-6. PubMed ID: 9426014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet glycoprotein IIb/IIIa receptor blockade in acute myocardial infarction associated with thrombotic occlusion of the left main coronary artery.
    Rechavia E; Wurzel M
    Circulation; 1998 Sep; 98(12):1249-50. PubMed ID: 9743517
    [No Abstract]   [Full Text] [Related]  

  • 7. Platelet glycoprotein IIb/IIIa receptor blockade therapy for large coronary aneurysms and thrombi in Kawasaki disease.
    Etheridge SP; Tani LY; Minich LL; Revenaugh JR
    Cathet Cardiovasc Diagn; 1998 Nov; 45(3):264-8. PubMed ID: 9829884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coronary artery stenting for suboptimal PTCA results in acute myocardial infarction in patients treated with Abciximab: early and six-month outcome.
    Murdock DK; Logemann T; Hoffmann MT; Olson KJ; Engelmeier RS
    Cathet Cardiovasc Diagn; 1997 Oct; 42(2):173-9. PubMed ID: 9328702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
    Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
    N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. "Rescue" utilization of abciximab for the dissolution of coronary thrombus developing as a complication of coronary angioplasty.
    Muhlestein JB; Karagounis LA; Treehan S; Anderson JL
    J Am Coll Cardiol; 1997 Dec; 30(7):1729-34. PubMed ID: 9385900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Large intracoronary thrombi with good TIMI flow during acute myocardial infarction: four cases of successful aggressive medical management in patients without angiographically detectable coronary atherosclerosis.
    Burzotta F; Hamon M; Sabatier R; Prati F; Boccanelli A; Grollier G
    Heart; 2002 Nov; 88(5):e6. PubMed ID: 12381657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.
    Lincoff AM; Tcheng JE; Califf RM; Kereiakes DJ; Kelly TA; Timmis GC; Kleiman NS; Booth JE; Balog C; Cabot CF; Anderson KM; Weisman HF; Topol EJ
    Circulation; 1999 Apr; 99(15):1951-8. PubMed ID: 10208997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coronary embolism following aortic and mitral valve replacement: successful management with abciximab and urokinase.
    Quinn EG; Fergusson DJ
    Cathet Cardiovasc Diagn; 1998 Apr; 43(4):457-9. PubMed ID: 9554780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "Rescue" abciximab for complicated percutaneous transluminal coronary angioplasty.
    Garbarz E; Farah B; Vuillemenot A; André F; Angioï M; Machecourt J; Bassand JP; Wolf JE; Danchin N; Prendergast B; Iung B; Vahanian A
    Am J Cardiol; 1998 Sep; 82(6):800-3, A9. PubMed ID: 9761094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Quick resolution with abciximab of giant coronary thrombus].
    Delcán Domínguez JL; García Fernández E; Guerrero Sanz JE
    Rev Esp Cardiol; 2002 May; 55(5):536. PubMed ID: 12015935
    [No Abstract]   [Full Text] [Related]  

  • 16. Instant dissolution of intracoronary thrombus by abciximab.
    Lee CH; Ho KT; Tan HC
    Int J Cardiol; 2005 Sep; 104(1):102-3. PubMed ID: 16137518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Adjuvant therapy with a glycoprotein IIb-IIa inhibitor (abciximab) in coronary angioplasties with a high thrombotic risk].
    Matos V; Marques AM; Oliveira H; Ramos D; Lopes P; Camacho M; Gonsalves A
    Rev Port Cardiol; 1998 Dec; 17(12):1001-5. PubMed ID: 9973861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis.
    Claeys MJ; Van der Planken MG; Bosmans JM; Michiels JJ; Vertessen F; Van Der Goten P; Wuyts FL; Vrints CJ
    Eur Heart J; 2005 Mar; 26(6):567-75. PubMed ID: 15618034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accessibility of abciximab to megakaryocytes and endothelial cells in the bone marrow compartment: studies on a patient receiving antithrombotic therapy.
    Poujol C; Durrieu-Jais C; Larrue B; Nurden AT; Nurden P
    Br J Haematol; 1999 Dec; 107(3):526-31. PubMed ID: 10583253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preferential benefit of platelet glycoprotein IIb/IIIa receptor blockade: specific considerations by device and disease state.
    Kereiakes DJ
    Am J Cardiol; 1998 Apr; 81(7A):49E-54E. PubMed ID: 9551595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.